INSIGHTEC develops the world’s foremost MR-guided Focused Ultrasound treatment platform for a variety of neurosurgery, oncology and gynecology indications. Treatments are totally non invasive, safe and effective, and are performed in ambulatory setting.

1. CORPORATE
PRESENTATION
December 2015

2. ONCOLOGYNEUROSURGERY
WOMAN’S
HEALTH
THE GLOBAL
LEADER OF
MRGFUS
INSIGHTEC develops the world’s foremost
MR-guided Focused Ultrasound treatment
platform for a variety of neurosurgery,
oncology and gynecology indications.
Treatments are totally non invasive,
safe and effective, and are performed in
ambulatory setting

3. COMPANY PROFILE
• Developed Exablate® - the first
FDA approved therapeutic device
using MR-guided Focused
Ultrasound
• INSIGHTEC is a privately held
Israeli company founded in 1999
• ~160 employees worldwide
• First to develop technology to
successfully steer and focus
ultrasound through the cranium
Headquartered
in Haifa, Israel.
Regional offices
in US, China,
Japan and
Europe.

4. www.insightec.com
INSIGHTEC’S TECHNOLOGY
Non invasive therapy platform that
combines two proven technologies -
High intensity focused ultrasound and
Magnetic Resonance Imaging.
The high intensity focused ultrasound
(FUS) generates heat at the focal point
to ablate the target tissue.
The MRI enables:
1. to identify and target
2. to monitor in real time the
treatment progress using
thermometry information.

5. 3 PRODUCT
FAMILIES
ONCOLOGY
NEUROSURGERY
WOMAN’S
HEALTH

6. INSIGHTEC
PRODUCT
ROADMAP –
NEUROSURGERY
• Small volume treatments
• Deep central structures
treatment envelop
• Normal tissues (at MR)
• Thermal ablation
• Larger volume treatments
• Whole brain treatment envelop
• Pathologic tissues (at MR)
• Thermal ablation & Targeted
Drug Delivery
2010 2012 2015
2016+
Neuropathic
Pain
Essential
Tremor
Parkinson's
Disease
Brain
Tumors
Epilepsy Targeted Drug
Delivery
Alzheimer
Neuro-
Modulation

7. • Outpatient, low risk profile
• Real time close loop personalized
therapy
• Tumors’ conformal treatment
• Pathologic tissues (based on MR)
• Larger volume treatments
• Faster treatment rate
• Treatment of moving organs
• Non-heating properties of US
2004 2012 2013
2016+
Gynecology Bone
Tumors
Facets Prostate Liver Pancreas Targeted
Drug
Delivery
2015
INSIGHTEC PRODUCT
ROADMAP –
WOMEN’S HEALTH &
ONCOLOGY

8. WOMEN'S
HEALTH
Treatments for
uterine fibroids
• Single-session, outpatient
treatment
• Uterus preserving
• Future fertility
• Minimal complications and
adverse events
• Durable as other uterine sparing
treatments’ alternatives

9. ONCOLOGY
Treatments for pain
palliation of bone
metastases
• Single-session
• Non-ionizing
• Minimal complications and
adverse events
• Very fast post procedure pain
relief

10. ONCOLOGYNEUROSURGERY
Treatments for
Essential Tremor,
Tremor dominant
Parkinson’s Disease,
Neuropathic Pain
• Single session
• Noninvasive procedure
• No ionizing radiation
• No penetrating trajectories
with probes
• No implantable hardware
• No anesthesia
• No infectious risks

11. OUR TECHNOLOGY
BODY PLATFORM
• Embedded phased array ultrasound
transducer (200 to 1,000
independently controlled
transducers)
• Real time treatment monitoring
• Interchangeable cradles for multiple
applications
• Interfaces with GE MRIs (1.5T and
3T scanners)

12. • 1000 element spherical phase array
transducer
• Sharp boundaries between treated and
untreated areas
• Focal point controlled electronically in
size (2-5mm) and location (<1mm
accuracy)
• Real-time MR monitoring of temperature
• Interfaces with GE MRIs (1.5T and 3T
scanners)
OUR TECHNOLOGY
NEURO PLATFORM

13. OUR TECHNOLOGY
BODY PLATFORM
• Treatment planning while
recognizing and avoiding
sensitive tissue
• Real-time treatment outcome
monitoring using MR
thermometry
• MRI based real time motion
detection and compensation in
treatment plan

14. REGULATORY
STATUS
NEUROSURGERY ONCOLOGY
WOMEN'S
HEALTH
• Essential tremor
• Tremor, dominan
t, Parkinson’s,
Diseases
• Neuropathic pain
• Pain palliation of
bone metastasis
• Primary bone
tumors
• Bone metastasis
• Uterine fibroids (Future
fertility)
• Uterine fibroids &
Adenomyosis (Future
fertility)
• Commercially approved in
Japan, Australia, China,
Korea and Russia

15. OUR GLOBAL
FOOTPRINT
An install base of ~120 sites around
the globe, our customers include
well-renowned centers of excellence
Americas
18 USA
2 Canada
1 Mexico
2 Brazil
Europe
4 Germany
11 Italy
4 UK
2 Switzerland
1 Spain
1 Poland
3 France
1 Czech
Republic
Asia
14 Japan
4 Korea
5 China
2 Singapore
1 Taiwan
1 Malaysia
2 Australia
7 India
1 Vietnam
2 GE
17 Russia
1
Kazakhstan
3 Israel
1 HK

16. THANK YOU!